Reference Detail

Ref Type

PMID

Authors

Funda Meric-Bernstam, Michael Rothe, Elizabeth Garrett-Mayer, Rodolfo Gutierrez, Eugene R Ahn, Timothy Lewis Cannon, Steven Francis Powell, John C. Krauss, Christopher M. Reynolds, Margaret von Mehren, Deepti Behl, Carmen Julia Calfa, Herbert Leon Duvivier, Henry G. Kaplan, Michael B. Livingston, Manish Sharma, Walter John Urba, Raegan O'Lone, Susan Halabi, Richard L. Schilsky

Title

Cobimetinib plus vemurafenib (C+V) in patients (Pts) with solid tumors with BRAF V600E/d/k/R mutation: Results from the targeted agent and profiling utilization registry (TAPUR) study.

Journal	Vol	Issue	Date	Pages	Journal Short Title
Journal of Clinical Oncology	40	no. 16_suppl

URL

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3008

Abstract Text

Background:TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort of pts with solid tumors with BRAF V600E/D/K/R mutation (mut) treated with C+V are reported. Methods: Eligible pts had advanced solid tumors, no standard treatment (tx) options, measurable disease, ECOG performance status (PS) 0-2, and adequate organ function. Genomic testing was performed in CLIA-certified, CAP-accredited site selected labs. Pts matched to C+V had various solid tumors with BRAF V600E/D/K/R mut, or other BRAF mut if approved by the Molecular Tumor Board, and no MAP2K1/2, MEK1/2, NRAS mut. Recommended dosing was C, 60 mg orally daily for 21 days, 7 days off and V, 960 mg orally every 12 hours. Primary endpoint was disease control (DC), defined as complete (CR) or partial (PR) response or stable disease at 16+ wks (SD 16+) (RECIST v1.1). Low accruing histology-specific cohorts with the same genomic target and tx were collapsed into a single histology-pooled cohort for this analysis. For histology-pooled cohorts with sample size of 28, the results are evaluated based on a one-sided exact binomial test with a null DC rate of 15% vs. 35% (power = 0.84; α = 0.10) and one-sided 90% confidence interval (CI). Other efficacy endpoint estimates are presented with two-sided 95% CIs. Secondary endpoints were progression-free survival (PFS), overall survival (OS) and safety. Results: 31pts with solid tumors (13 histologies; 6/31 ovarian cancer) with BRAF muts were enrolled from Dec 2016 to Jan 2021 and collapsed into one histology pooled cohort for analysis. 3 pts were not evaluable due to lack of post-baseline tumor evaluation and excluded from efficacy analyses. Demographics and outcomes are summarized in the Table. Pts had tumors with BRAF V600E mut (N = 26), G469V mut (N = 1), K601E mut (N = 2), N581I (N = 1) and T599_V600insT (N = 1). 2 CR (breast and ovarian cancer; V600E), 14 PR (13 V600E, 1 N581I), and 3 SD16+ (2 V600E, 1 T599_V600insT) were observed for a DC rate of 68% (90% CI: 54%, 100%) and an objective response (OR) rate of 57% (95% CI: 37%, 76%). CR durations were 5.1 (ovarian cancer) and 108.9 wks (breast cancer) and median duration of PR was 20.5 wks (range: 8.0, 176.0). 19 pts experienced ≥1 Grade 1-5 AE/SAE at least possibly related to tx including 1 death attributed to tx-related kidney injury. Conclusions:C+Vdemonstrated evidence of anti-tumor activity in pts with advanced solid tumors with BRAF V600E and other muts. Clinical trial information: NCT02693535.

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References